In ATOMIC, 36-month disease-free survival was 86% with Tecentriq plus chemotherapy versus 76% with chemotherapy alone; Roche is pursuing European filings.
In the 712-patient ATOMIC trial, 36-month disease-free survival was 86% with Tecentriq plus chemotherapy, versus 76% with chemotherapy alone.
Underwriters may buy up to 300,000 more shares under a 30-day option. Closing is expected Oct. 19; proceeds are intended for a life-sciences loan commitment.
Crescent plans to use proceeds for part of the cash consideration for Devon’s Eagle Ford assets acquisition, expected to close in Q4 2026 or early 2027.
Net proceeds and existing cash are intended to complete Phase 2b and prepare for a planned Phase 3 trial of RTN-001; the IPO ...
The Third Circuit invited U.S. views by Oct. 13; no filing had arrived as of Oct. 8. Venezuela's motion seeks time to pursue ...
The five-day program runs Oct. 7-11; remaining care packages will go to people in need, and NBA legends and coaches will ...
Underwriters have a 30-day option to buy up to 1.25 million additional shares; the offering is expected to close Oct. 13, subject to customary conditions.
Code Guardian tests isolated copies of customer code against multi-step attack scenarios; the system is in private preview ...
Recent: Retension Pharmaceuticals Announces Pricing of Initial Public Offering . Track all RTSN press releases, SEC filings, and market updates. Latest RTSN news updated today, October 8.
CMS rated Clover’s HMO plan 4.5 stars; with 20 measures included, its PPO rating would be 4.5. Clover’s HEDIS score was 4.82 ...
The trial also reported complete symptom resolution at 11.95 hours, no safety signals, and regulatory applications under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results